Pharma-Bio Serv, Inc.
Close on Oct 19, 2026
- Market cap
- $11.00M
- P/E (TTM)
- 48.0
- Dividend yield
- –
About Pharma-Bio Serv
Services-Management Consulting Services, SIC 8742
Pharma-Bio Serv provides technical compliance, regulatory affairs, quality, validation, engineering, project management, and technology transfer consulting services. Its business operates across three reportable segments: Puerto Rico technical compliance consulting, United States technical compliance consulting, and Europe technical compliance consulting. The firm serves clients in diverse regulated sectors, focusing on the pharmaceutical, biotechnology, chemical, medical device, cosmetic, and food manufacturing industries.
Headquartered in Puerto Rico, the company conducts its operations and marketing efforts across Puerto Rico, the United States, Europe, and Brazil. Its workforce consists of approximately 55 full-time employees and 20 independent contractors who support technical projects. Furthermore, the company services around 70 commercial clients, maintaining consistent consulting engagements with major life science and healthcare manufacturing organizations throughout its active geographic territories.
Summary of the business section of Pharma-Bio Serv's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pharma-Bio Serv, Inc.
- Founded
- 2004
- Headquarters
- Dorado, PR
- Address
- Industrial Zone Street 1, Lot 14 00646
- Phone
- (787) 278-2709
- Website
- pbsvinc.com
- Employees
- 190, Oct 31, 2021
- Industry
- Services-Management Consulting Services
- Fiscal year ends
- October 31
- Auditor
- CROWE PR PSC, Guaynabo, Puerto Rico
Stock & identifiers
- Ticker
- PBSV
- Exchange
- OTC
- Shares outstanding
- 23M, Sep 10, 2026
- Public float
- $13.64M, Apr 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1304161
- EIN
- 20-0653570
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Kirk Wheeler Michel | Chairman, Director | 398,648 |
| Howard Spindel | Director | 0 |
| Irving L. Wiesen | Director | 67,241 |
| Dov Perlysky | Director | 2,004,539 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Victor Sanchez | $245.90K | $245.30K | $175.60K | $76740 | – |
| FY2024 Victor Sanchez | $245.90K | $241.23K | $181.90K | $74030 | – |
| FY2023 Victor Sanchez | $323.67K | $321.50K | $225.60K | $89150 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“We employ approximately 190 employees, all of whom are full time employees.”
Corporate history
Events identified from SEC filings